Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 7/20 | 0.49 |
| ▸ | MMP14 | P50281 | 4/20 | 0.49 |
| ▸ | MMP7 | P09237 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 6/20 | 0.46 |
| ▸ | MMP9 | P14780 | 6/20 | 0.46 |
| ▸ | MMP13 | P45452 | 5/20 | 0.46 |
| ▸ | MMP12 | P39900 | 4/20 | 0.46 |
| ▸ | ADAMTS4 | O75173 | 3/20 | 0.46 |
| ▸ | MMP8 | P22894 | 3/20 | 0.46 |
| ▸ | MMP16 | P51512 | 3/20 | 0.46 |
| ▸ | MMP3 | P08254 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1464395 | 0.88 | HSD11B1 (0.48) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL11446251 | 0.86 | MMP2 (0.51) | MMP2MMP7MMP1MMP9MMP13 | |
| SCHEMBL1464762 | 0.81 | ALDH1A1 (0.47) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL2227158 | 0.81 | ENPP2 (0.48) | — | |
| SCHEMBL1464437 | 0.80 | MMP1 (0.45) | MMP2MMP14MMP7MMP1MMP9 | |
| SCHEMBL2702059 | 0.80 | ALDH1A1 (0.57) | MMP2MMP14MMP7CA12CA1 | |
| SCHEMBL352118 | 0.79 | CNR2 (0.52) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL766883 | 0.79 | PHGDH (0.48) | MMP2MMP7CA1CA2MMP1 | |
| SCHEMBL17908079 | 0.79 | CA2 (0.52) | CA12CA1CA2CA9 | |
| SCHEMBL1464736 | 0.77 | LMNA (0.49) | CA2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299111-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| US-8299111-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| US-8299111-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| EP-2081905-B1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2012-09-12 | — | — | EP | disclosed |
| US-7935715-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-03 | — | — | US | disclosed |
| US-7935715-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-03 | — | — | US | disclosed |
| US-7935715-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-03 | — | — | US | disclosed |
| US-20110071127-A1 | Compounds Which Modulate the CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20110071127-A1 | Compounds Which Modulate the CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20110071127-A1 | Compounds Which Modulate the CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | MMP2 2933/4885MMP14 3843/4885MMP7 3831/4885 |
| US-20110071127-A1 | Compounds Which Modulate the CB2 Receptor | CNR2, CNR1, OPRL1 | MMP2 2815/4885MMP14 3838/4885MMP7 3758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.